Fas-associated factor 1 and Parkinson's disease

Neurobiology of Disease

Volumn 31, Issue 3, 2008, Pages 309-315

  Betarbet, Ranjita ^a   Anderson, Leah R ^b   Gearing, Marla ^a   Hodges, Tiffany R ^c   Fritz, Jason J ^a   Lah, James J ^a   Levey, Allan I ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

synuclein; Cell death; Mitochondrial inhibition; Oxidative stress; PARK 10

Indexed keywords

ALPHA SYNUCLEIN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; PROTEASOME; PROTEIN FAF 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); UNCLASSIFIED DRUG;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL DEATH; CELL LOSS; CONTROLLED STUDY; EMBRYO; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; BRAIN; CELL DEATH; CELL LINE; CHROMOSOMES, HUMAN, PAIR 1; ELECTRON TRANSPORT COMPLEX I; ENERGY METABOLISM; FRONTAL LOBE; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; MITOCHONDRIA; NERVE DEGENERATION; NEURONS; OXIDATIVE STRESS; PARKINSON DISEASE; SUBSTANTIA NIGRA;

EID: 49449091601     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2008.05.006     Document Type: Article

References (32)

1. Abou-Sleiman P.M., Muqit M.M., and Wood N.W. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat. Rev. Neurosci. 7 (2006) 207-219
2. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., and Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease [In Process Citation]. Nat. Neurosci. 3 (2000) 1301-1306
3. Betarbet R., Canet-Aviles R.M., Sherer T.B., Mastroberardino P.G., McLendon C., Kim J.H., Lund S., et al. Intersecting pathways to neurodegeneration in Parkinson's disease: Effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiol. Dis. 22 (2006) 404-420
4. Braak H., Rub U., and Del Tredici K. Cognitive decline correlates with neuropathological stage in Parkinson's disease. J. Neurol. Sci (2006)
5. Chu K., Niu X., and Williams L.T. A Fas-associated protein factor, FAF1, potentiates Fas-mediated apoptosis. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 11894-11898
6. Ciliax B.J., Drash G.W., Staley J.K., Haber S., Mobley C.J., Miller G.W., Mufson E.J., et al. Immunocytochemical localization of the dopamine transporter in human brain. J. Comp. Neurol. 409 (1999) 38-56
7. Damier P., Hirsch E.C., Agid Y., and Graybiel A.M. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 122 (Pt 8) (1999) 1437-1448
8. Dawson T.M., and Dawson V.L. Molecular pathways of neurodegeneration in Parkinson's disease. Science. 302 (2003) 819-822
9. Duda J.E., Giasson B.I., Mabon M.E., Lee V.M., and Trojanowski J.Q. Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann. Neurol. 52 (2002) 205-210
10. Farrer M.J., Haugarvoll K., Ross O.A., Stone J.T., Milkovic N.M., Cobb S.A., Whittle A.J., et al. Genomewide association, Parkinson disease, and PARK10. Am. J. Hum. Genet. 78 (2006) 1084-1088 author reply 1092-4
11. Fernandes-Alnemri T., Litwack G., and Alnemri E.S. CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme. J. Biol. Chem. 269 (1994) 30761-30764
12. Forno L.S. The Lewy body in Parkinson's disease. Adv Neurol. 45 (1987) 35-43
13. Gherbassi D., Bhatt L., Thuret S., and Simon H.H. Merging mouse transcriptome analyses with Parkinson's disease linkage studies. DNA Res. 14 (2007) 79-89
14. Hicks A.A., Petursson H., Jonsson T., Stefansson H., Johannsdottir H.S., Sainz J., Frigge M.L., et al. A susceptibility gene for late-onset idiopathic Parkinson's disease. Ann. Neurol. 52 (2002) 549-555
15. Hornykiewicz O. Dopamine miracle: from brain homogenate to dopamine replacement. Mov. Disord. 17 (2002) 501-508
16. Jenner P. Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov. Disord. 13 (1998) 24-34
17. Kikyo N., Rideout 3rd W.M., Tada T., Tada M., and Surani M.A. Mapping of the Fas-associated factor 1 gene, Faf1, to mouse chromosome 4C6 by FISH. Mamm. Genome 8 (1997) 224-225
18. Klockgether T. Parkinson's disease: clinical aspects. Cell Tissue Res. 318 (2004) 115-120
19. McCormack A.L., Atienza J.G., Langston J.W., and Di Monte D.A. Decreased susceptibility to oxidative stress underlies the resistance of specific dopaminergic cell populations to paraquat-induced degeneration. Neuroscience. 141 (2006) 929-937
20. Miller G.W., Staley J.K., Heilman C.J., Perez J.T., Mash D.C., Rye D.B., and Levey A.I. Immunochemical analysis of dopamine transporter protein in Parkinson's disease. Ann. Neurol. 41 (1997) 530-539
21. Mirra S.S., Heyman A., McKeel D., Sumi S.M., Crain B.J., Brownlee L.M., Vogel F.S., et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 41 (1991) 479-486
22. Nagata S. Apoptosis by death factor. Cell. 88 (1997) 355-365
23. Nicholson D.W., Ali A., Thornberry N.A., Vaillancourt J.P., Ding C.K., Gallant M., Gareau Y., Griffin P.R., Labelle M., Lazebnik Y.A., et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature. 376 (1995) 37-43
24. Offe K., Dodson S.E., Shoemaker J.T., Fritz J.J., Gearing M., Levey A.I., and Lah J.J. The lipoprotein receptor LR11 regulates amyloid beta production and amyloid precursor protein traffic in endosomal compartments. J. Neurosci. 26 (2006) 1596-1603
25. Periquet M., Fulga T., Myllykangas L., Schlossmacher M.G., and Feany M.B. Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo. J. Neurosci. 27 (2007) 3338-3346
26. Ryu S.W., Chae S.K., Lee K.J., and Kim E. Identification and characterization of human Fas associated factor 1, hFAF1. Biochem. Biophys. Res. Commun. 262 (1999) 388-394
27. Ryu S.W., and Kim E. Apoptosis induced by human Fas-associated factor 1, hFAF1, requires its ubiquitin homologous domain, but not the Fas-binding domain. Biochem. Biophys. Res. Commun. 286 (2001) 1027-1032
28. Selkoe D.J. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann. N. Y. Acad. Sci. 924 (2000) 17-25
29. Sherer T.B., Betarbet R., Testa C.M., Seo B.B., Richardson J.R., Kim J.H., Miller G.W., et al. Mechanism of toxicity in rotenone models of Parkinson's disease. J. Neurosci. 23 (2003) 10756-10764
30. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., Hulihan M., et al. {alpha}-Synuclein locus triplication causes Parkinson's disease. Science. 302 (2003) 841
31. Vila M., and Przedborski S. Targeting programmed cell death in neurodegenerative diseases. Nat Rev Neurosci. 4 (2003) 365-375
32. Zhu C., Vourc'h P., Fernagut P.O., Fleming S.M., Lacan S., Dicarlo C.D., Seaman R.L., et al. Variable effects of chronic subcutaneous administration of rotenone on striatal histology. J. Comp. Neurol. 478 (2004) 418-426